Bosulif Recommended by SMC for Chronic Myeloid Leukaemia

The Scottish Medicines Consortium (SMC) has approved Pfizer’s Bosulif (bosutinib) for the treatment of adult patients with chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukaemia, within NHS Scotland. The treatment has been approved for patients who have previously been treated with one or more tyrosine kinase inhibitors, and for whom

Continue Reading

SMC Approves Bristol-Myers Squibb’s Daklinza and Yervoy

Scotland’s regulatory advisory committee, the Scottish Medicines Consortium (SMC) have granted approval to Bristol-Myers Squibb’s Daklinza and Yervoy for use on the NHS in Scotland. Specifically, Daklinza (daclatasvir) received regulatory approval for use with other drugs for the treatment of chronic hepatitis C virus infection in adults. The approval grants access to Daklinza as a

Continue Reading

Scotland Approves Novartis / ThromboGenics’ Jetrea and Roche’s RoActemra

The Scottish Medicines Consortium (SMC) has announced their latest set of recommendations approving regulatory submissions for Novartis and ThromboGenics’ eye therapy Jetrea and Roche’s RoActemra. The SMC have also announced rejections for the chronic obstructive pulmonary disease (COPD) drugs submitted for approval by Boehringer Ingelheim and GlaxoSmithKline (GSK).

Continue Reading